25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AKBA (Akebia) Stock Analysis
Buy, Hold or Sell?

Let's analyze Akebia together

I guess you are interested in Akebia Ther. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Akebia’s Financial Insights
  • 📈 Technical Analysis (TA) – Akebia’s Price Targets

I'm going to help you getting a better view of Akebia Ther. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Akebia Ther

I send you an email if I find something interesting about Akebia Ther.

1. Quick Overview

1.1. Quick analysis of Akebia (30 sec.)










1.2. What can you expect buying and holding a share of Akebia? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$0.09
Expected worth in 1 year
$0.29
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$0.20
Return On Investment
5.5%

For what price can you sell your share?

Current Price per Share
$3.62
Expected price per share
$2.48 - $4.0758
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Akebia (5 min.)




Live pricePrice per Share (EOD)
$3.62
Intrinsic Value Per Share
$-2.92 - $0.32
Total Value Per Share
$-2.82 - $0.42

2.2. Growth of Akebia (5 min.)




Is Akebia growing?

Current yearPrevious yearGrowGrow %
How rich?$24.5m-$31m$3.8m14.1%

How much money is Akebia making?

Current yearPrevious yearGrowGrow %
Making money-$11.3m-$10.7m-$570.2k-5.0%
Net Profit Margin-27.9%-27.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Akebia (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Akebia?

Welcome investor! Akebia's management wants to use your money to grow the business. In return you get a share of Akebia.

First you should know what it really means to hold a share of Akebia. And how you can make/lose money.

Speculation

The Price per Share of Akebia is $3.62. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Akebia.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Akebia, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.09. Based on the TTM, the Book Value Change Per Share is $0.05 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Akebia.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.020.6%-0.04-1.2%-0.04-1.1%-0.05-1.3%-0.16-4.3%-0.15-4.1%
Usd Book Value Change Per Share0.287.8%0.051.4%-0.01-0.3%0.000.0%-0.07-2.0%-0.01-0.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.287.8%0.051.4%-0.01-0.3%0.000.0%-0.07-2.0%-0.01-0.2%
Usd Price Per Share1.92-1.54-1.28-1.09-2.25-5.92-
Price to Earnings Ratio20.63-0.76-28.84-9.44-4.56--6.42-
Price-to-Total Gains Ratio6.84-88.70-34.58-37.85-10.45-16.96-
Price to Book Ratio20.51--1.11--11.21--2.99-0.46-11.44-
Price-to-Total Gains Ratio6.84-88.70-34.58-37.85-10.45-16.96-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.62
Number of shares276
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.05-0.07
Usd Total Gains Per Share0.05-0.07
Gains per Quarter (276 shares)13.62-19.53
Gains per Year (276 shares)54.48-78.14
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1054440-78-88
20109980-156-166
301631520-234-244
402182060-313-322
502722600-391-400
603273140-469-478
703813680-547-556
804364220-625-634
904904760-703-712
1005455300-781-790

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%3.09.00.025.0%3.017.00.015.0%4.036.00.010.0%4.046.00.08.0%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%5.015.00.025.0%13.027.00.032.5%16.032.02.032.0%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%2.00.048.04.0%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%5.015.00.025.0%13.027.00.032.5%16.032.02.032.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Akebia Ther compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2810.049+469%-0.012+104%0.000+100%-0.071+125%-0.007+102%
Book Value Per Share--0.094-0.104+211%-0.118+226%-0.051+155%0.267-65%0.580-84%
Current Ratio--2.2341.552+44%1.385+61%1.438+55%1.590+40%3.531-37%
Debt To Asset Ratio--0.9211.135-19%1.130-19%1.078-15%0.927-1%0.697+32%
Debt To Equity Ratio--11.6192.905+300%-+100%7.177+62%6.153+89%3.848+202%
Dividend Per Share----0%-0%0.000-100%0.000-100%0.000-100%
Enterprise Value--332031120.000197411690.000+68%112758875.000+194%53001393.433+526%374981224.280-11%1456768322.140-77%
Eps--0.023-0.043+285%-0.041+276%-0.046+300%-0.155+766%-0.149+739%
Ev To Ebitda Ratio--6.142-1.933+131%-5.164+184%-0.326+105%-1.178+119%-9.266+251%
Ev To Sales Ratio--1.4481.022+42%0.745+94%0.387+274%1.497-3%544.560-100%
Free Cash Flow Per Share---0.052-0.033-36%-0.024-54%-0.041-21%-0.081+56%-0.088+70%
Free Cash Flow To Equity Per Share--0.2340.068+244%-0.015+107%-0.020+109%-0.001+100%0.001+37844%
Gross Profit Margin--1.0001.0000%-8.360+936%-2.033+303%-0.594+159%0.289+246%
Intrinsic Value_10Y_max--0.323----------
Intrinsic Value_10Y_min---2.918----------
Intrinsic Value_1Y_max---0.136----------
Intrinsic Value_1Y_min---0.344----------
Intrinsic Value_3Y_max---0.280----------
Intrinsic Value_3Y_min---0.995----------
Intrinsic Value_5Y_max---0.269----------
Intrinsic Value_5Y_min---1.599----------
Market Cap950742320.000+47%504261120.000404459440.000+25%336502375.000+50%286529310.100+76%591122724.280-15%1553916097.140-68%
Net Profit Margin--0.107-0.279+362%-0.271+354%-0.307+388%-0.727+782%-12.036+11391%
Operating Margin----0.2120%-0.2260%-0.2740%-0.6760%-12.1590%
Operating Ratio--0.7521.148-35%1.225-39%1.241-39%1.661-55%13.815-95%
Pb Ratio38.678+47%20.514-1.112+105%-11.210+155%-2.986+115%0.460+4363%11.437+79%
Pe Ratio38.888+47%20.6260.757+2626%28.844-28%9.440+118%4.556+353%-6.416+131%
Price Per Share3.620+47%1.9201.540+25%1.281+50%1.091+76%2.251-15%5.917-68%
Price To Free Cash Flow Ratio-17.470-89%-9.266-14.206+53%-8.837-5%-7.925-14%-4.902-47%-8.926-4%
Price To Total Gains Ratio12.889+47%6.83688.701-92%34.581-80%37.847-82%10.453-35%16.963-60%
Quick Ratio--1.9171.355+42%0.879+118%1.062+80%1.268+51%4.955-61%
Return On Assets--0.020-0.055+378%-0.046+332%-0.047+337%-0.081+512%-0.089+553%
Return On Equity--0.2490.062+300%-+100%-0.353+242%-0.498+300%-0.375+251%
Total Gains Per Share--0.2810.049+469%-0.012+104%0.000+100%-0.071+125%-0.007+102%
Usd Book Value--24581000.000-27190000.000+211%-31017750.000+226%-13474000.000+155%70119800.000-65%152279175.000-84%
Usd Book Value Change Per Share--0.2810.049+469%-0.012+104%0.000+100%-0.071+125%-0.007+102%
Usd Book Value Per Share--0.094-0.104+211%-0.118+226%-0.051+155%0.267-65%0.580-84%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%0.000-100%
Usd Enterprise Value--332031120.000197411690.000+68%112758875.000+194%53001393.433+526%374981224.280-11%1456768322.140-77%
Usd Eps--0.023-0.043+285%-0.041+276%-0.046+300%-0.155+766%-0.149+739%
Usd Free Cash Flow---13605000.000-8708500.000-36%-6319500.000-54%-10765333.333-21%-21257400.000+56%-23118600.000+70%
Usd Free Cash Flow Per Share---0.052-0.033-36%-0.024-54%-0.041-21%-0.081+56%-0.088+70%
Usd Free Cash Flow To Equity Per Share--0.2340.068+244%-0.015+107%-0.020+109%-0.001+100%0.001+37844%
Usd Market Cap950742320.000+47%504261120.000404459440.000+25%336502375.000+50%286529310.100+76%591122724.280-15%1553916097.140-68%
Usd Price Per Share3.620+47%1.9201.540+25%1.281+50%1.091+76%2.251-15%5.917-68%
Usd Profit--6112000.000-11328250.000+285%-10758000.000+276%-11691500.000+291%-40609850.000+764%-39679750.000+749%
Usd Revenue--57336000.00046227250.000+24%46806250.000+22%53597000.000+7%56263500.000+2%48403950.000+18%
Usd Total Gains Per Share--0.2810.049+469%-0.012+104%0.000+100%-0.071+125%-0.007+102%
 EOD+5 -3MRQTTM+27 -9YOY+30 -73Y+29 -105Y+24 -1510Y+21 -18

3.3 Fundamental Score

Let's check the fundamental score of Akebia Ther based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1538.888
Price to Book Ratio (EOD)Between0-138.678
Net Profit Margin (MRQ)Greater than00.107
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.917
Current Ratio (MRQ)Greater than12.234
Debt to Asset Ratio (MRQ)Less than10.921
Debt to Equity Ratio (MRQ)Less than111.619
Return on Equity (MRQ)Greater than0.150.249
Return on Assets (MRQ)Greater than0.050.020
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Akebia Ther based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.457
Ma 20Greater thanMa 503.668
Ma 50Greater thanMa 1003.069
Ma 100Greater thanMa 2002.512
OpenGreater thanClose3.630
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Akebia Ther

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-06-18 22:46:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Akebia earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 10.7% means that $0.11 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akebia Ther:

  • The MRQ is 10.7%. The company is making a huge profit. +2
  • The TTM is -27.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ10.7%TTM-27.9%+38.6%
TTM-27.9%YOY-27.1%-0.8%
TTM-27.9%5Y-72.7%+44.8%
5Y-72.7%10Y-1,203.6%+1,130.9%
4.3.1.2. Return on Assets

Shows how efficient Akebia is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.0% Return on Assets means that Akebia generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akebia Ther:

  • The MRQ is 2.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is -5.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ2.0%TTM-5.5%+7.5%
TTM-5.5%YOY-4.6%-0.9%
TTM-5.5%5Y-8.1%+2.6%
5Y-8.1%10Y-8.9%+0.8%
4.3.1.3. Return on Equity

Shows how efficient Akebia is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • 24.9% Return on Equity means Akebia generated $0.25 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akebia Ther:

  • The MRQ is 24.9%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 6.2%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ24.9%TTM6.2%+18.6%
TTM6.2%YOY-+6.2%
TTM6.2%5Y-49.8%+56.0%
5Y-49.8%10Y-37.5%-12.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Akebia Ther.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Akebia is operating .

  • Measures how much profit Akebia makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akebia Ther:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-21.2%+21.2%
TTM-21.2%YOY-22.6%+1.4%
TTM-21.2%5Y-67.6%+46.5%
5Y-67.6%10Y-1,215.9%+1,148.2%
4.3.2.2. Operating Ratio

Measures how efficient Akebia is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.75 means that the operating costs are $0.75 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Akebia Ther:

  • The MRQ is 0.752. The company is efficient in keeping operating costs low. +1
  • The TTM is 1.148. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.752TTM1.148-0.396
TTM1.148YOY1.225-0.076
TTM1.1485Y1.661-0.513
5Y1.66110Y13.815-12.154
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Akebia Ther.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Akebia is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.23 means the company has $2.23 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Akebia Ther:

  • The MRQ is 2.234. The company is able to pay all its short-term debts. +1
  • The TTM is 1.552. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.234TTM1.552+0.682
TTM1.552YOY1.385+0.167
TTM1.5525Y1.590-0.038
5Y1.59010Y3.531-1.942
4.4.3.2. Quick Ratio

Measures if Akebia is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.92 means the company can pay off $1.92 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akebia Ther:

  • The MRQ is 1.917. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.355. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.917TTM1.355+0.563
TTM1.355YOY0.879+0.476
TTM1.3555Y1.268+0.087
5Y1.26810Y4.955-3.687
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Akebia Ther.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Akebia assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akebia to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.92 means that Akebia assets are financed with 92.1% credit (debt) and the remaining percentage (100% - 92.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akebia Ther:

  • The MRQ is 0.921. The company is just able to pay all its debts by selling its assets.
  • The TTM is 1.135. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ0.921TTM1.135-0.214
TTM1.135YOY1.130+0.005
TTM1.1355Y0.927+0.208
5Y0.92710Y0.697+0.230
4.5.4.2. Debt to Equity Ratio

Measures if Akebia is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 1,161.9% means that company has $11.62 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akebia Ther:

  • The MRQ is 11.619. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.905. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ11.619TTM2.905+8.714
TTM2.905YOY-+2.905
TTM2.9055Y6.153-3.249
5Y6.15310Y3.848+2.305
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Akebia generates.

  • Above 15 is considered overpriced but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 20.63 means the investor is paying $20.63 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akebia Ther:

  • The EOD is 38.888. Based on the earnings, the company is overpriced. -1
  • The MRQ is 20.626. Based on the earnings, the company is fair priced.
  • The TTM is 0.757. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD38.888MRQ20.626+18.262
MRQ20.626TTM0.757+19.869
TTM0.757YOY28.844-28.088
TTM0.7575Y4.556-3.800
5Y4.55610Y-6.416+10.972
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Akebia Ther:

  • The EOD is -17.470. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.266. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -14.206. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.470MRQ-9.266-8.204
MRQ-9.266TTM-14.206+4.940
TTM-14.206YOY-8.837-5.369
TTM-14.2065Y-4.902-9.304
5Y-4.90210Y-8.926+4.023
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Akebia is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Akebia Ther:

  • The EOD is 38.678. Based on the equity, the company is expensive. -2
  • The MRQ is 20.514. Based on the equity, the company is expensive. -2
  • The TTM is -1.112. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD38.678MRQ20.514+18.164
MRQ20.514TTM-1.112+21.626
TTM-1.112YOY-11.210+10.099
TTM-1.1125Y0.460-1.571
5Y0.46010Y11.437-10.977
4.6.2. Total Gains per Share

2.4. Latest News of Akebia Ther

Does Akebia Ther still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Akebia Ther to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-01
22:05
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Akebia Ther.

4.8.1. Institutions holding Akebia Ther

Institutions are holding 38.865% of the shares of Akebia Ther.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc5.83780.0006153321632345381.5535
2025-03-31Vanguard Group Inc4.83020.000412685803180160316.5525
2025-03-31State Street Corp2.59130.000568058075011097.9482
2024-12-31SATTER MANAGEMENT CO., L.P.2.188519.2271574790600
2025-03-31Geode Capital Management, LLC1.91550.000850307402356454.9143
2025-03-31Great Point Partners LLC1.89385.0582497384049738400
2025-03-31Renaissance Technologies Corp1.52520.011640058271823004.7678
2025-03-31Citadel Advisors Llc1.38860.001336469092264763163.8584
2025-03-31AIGH Capital Management, LLC1.11372.3249292500029250000
2025-03-31Goldman Sachs Group Inc1.03730.000927244391722245171.8475
2025-03-31Morgan Stanley - Brokerage Accounts1.02090.0004268119889114749.7833
2025-03-31Franklin Resources Inc1.01560.0015266732725001431495.4439
2025-03-31Woodline Partners LP0.94640.031248557824855780
2025-03-31Nantahala Capital Management, LLC0.76150.1526200000020000000
2025-03-31The Informed Momentum Company (formerly EAM Investors)0.67690.5903177791117779110
2025-03-31Northern Trust Corp0.65150.00051711191255501.5157
2025-03-31Jacobs Levy Equity Management, Inc.0.60130.012157935535064528.5377
2025-03-31Affinity Asset Advisors, LLC0.57110.2749150000015000000
2025-03-31Monashee Investment Management LLC0.57110.3408150000015000000
2025-03-31Balyasny Asset Management LLC0.47420.0041245494971042353.8112
Total 31.612428.034383026488+28843059+34.7%

4.9.2. Funds holding Akebia Ther

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv2.98610.0011784258100
2025-05-31iShares Russell 2000 ETF2.08420.0269547388200
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.21530.0076319174553410.1676
2025-05-31SPDR® S&P Biotech ETF0.90530.15352377649140700.5953
2025-03-31Fidelity Small Cap Index0.81850.01712149663827724.0047
2025-05-31iShares Russell 2000 Value ETF0.68080.0505178807200
2025-05-31Franklin Biotechnology Discv A(acc)USD0.61110.3888160500000
2025-03-31Foord Global Equity (Lux) A0.60570.7252159077915907790
2025-03-31Foord Global Equity Class B0.55760.7322146438614643860
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.47840.0093125652100
2024-12-31RTW Biotech Opportunities Ord0.45355.2374119101011910100
2025-04-30Fidelity Extended Market Index0.41830.00741098508-10500-0.9468
2025-04-30Vanguard Russell 2000 ETF0.41250.02211083489718397.1012
2025-04-30IMC US Small Cap0.36770.676796577800
2025-04-30Franklin Biotechnology Discovery A0.34080.304589500000
2025-03-31Federated Hermes MDT SCG Institutional0.30830.348280971300
2025-03-31Federated Hermes MDT Small Cap Growth IS0.30830.347980971300
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.28990.026776150000
2025-05-30Fidelity Enhanced Small Cap ETF0.24150.10863436900
2025-04-30Schwab Small Cap Index0.20490.0222538160150502.877
Total 14.28879.213337527518+4424747+11.8%

5.3. Insider Transactions

Insiders are holding 3.593% of the shares of Akebia Ther.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-09Richard C MalabreSELL150004.01
2025-06-04Richard C MalabreSELL133343.53
2025-02-03John P ButlerSELL1442502.1
2025-02-03Nicholas GrundSELL556212.1
2025-02-03Richard C MalabreSELL302022.1
2025-02-03Steven Keith BurkeSELL505062.1
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Total Stockholder Equity -27,258-6,496-33,754-16,648-50,4021,217-49,18573,76624,581
Income before Tax  -17,9859,403-8,582-11,457-20,039-2,765-22,80428,9166,112
Net Income  -17,9859,403-8,582-11,457-20,039-2,765-22,80428,9166,112
Operating Income  -14,8786,153-8,725-3,780-12,505-1,802-14,30727,82113,514
Net Income from Continuing Operations  -17,9859,403-8,582-11,457-20,039-2,765-22,80428,9166,112



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets310,185
Total Liabilities285,604
Total Stockholder Equity24,581
 As reported
Total Liabilities 285,604
Total Stockholder Equity+ 24,581
Total Assets = 310,185

Assets

Total Assets310,185
Total Current Assets203,782
Long-term Assets106,403
Total Current Assets
Cash And Cash Equivalents 113,374
Net Receivables 61,538
Inventory 19,732
Other Current Assets 9,138
Total Current Assets  (as reported)203,782
Total Current Assets  (calculated)203,782
+/-0
Long-term Assets
Property Plant Equipment 9,018
Goodwill 59,044
Long-term Assets Other 38,341
Long-term Assets  (as reported)106,403
Long-term Assets  (calculated)106,403
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities91,227
Long-term Liabilities194,377
Total Stockholder Equity24,581
Total Current Liabilities
Short-term Debt 5,514
Accounts payable 12,658
Other Current Liabilities 71,814
Total Current Liabilities  (as reported)91,227
Total Current Liabilities  (calculated)89,986
+/- 1,241
Long-term Liabilities
Long term Debt 46,511
Capital Lease Obligations 7,637
Long-term Liabilities Other 104,103
Long-term Liabilities  (as reported)194,377
Long-term Liabilities  (calculated)158,251
+/- 36,126
Total Stockholder Equity
Common Stock2
Retained Earnings -1,672,248
Accumulated Other Comprehensive Income 6
Other Stockholders Equity 1,696,821
Total Stockholder Equity (as reported)24,581
Total Stockholder Equity (calculated)24,581
+/-0
Other
Capital Stock2
Cash and Short Term Investments 113,374
Common Stock Shares Outstanding 241,603
Current Deferred Revenue1,241
Liabilities and Stockholders Equity 310,185
Net Debt -59,226
Net Invested Capital 71,092
Net Working Capital 112,555
Property Plant and Equipment Gross 9,018
Short Long Term Debt Total 54,148



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
2,244
0
0
38,470
34,665
134,028
126,358
120,170
110,995
103,459
155,665
159,588
142,940
221,440
195,635
169,118
300,216
259,256
336,822
338,589
364,247
442,713
413,781
403,826
996,540
890,793
823,528
795,220
771,201
787,719
745,174
676,143
644,139
628,703
611,863
602,267
525,550
535,356
521,804
435,894
351,830
276,858
253,712
234,998
241,703
225,477
220,196
207,142
220,670
310,185
310,185220,670207,142220,196225,477241,703234,998253,712276,858351,830435,894521,804535,356525,550602,267611,863628,703644,139676,143745,174787,719771,201795,220823,528890,793996,540403,826413,781442,713364,247338,589336,822259,256300,216169,118195,635221,440142,940159,588155,665103,459110,995120,170126,358134,02834,66538,470002,244
   > Total Current Assets 
2,244
1,641
0
38,465
33,431
133,739
126,051
119,840
110,480
102,695
154,962
158,804
141,017
219,530
192,522
165,147
296,321
255,053
332,389
333,938
358,356
436,981
407,417
397,526
468,275
347,233
316,396
299,008
309,533
340,756
449,102
391,000
371,437
365,017
331,076
330,084
272,010
302,687
304,163
237,512
184,949
120,719
118,447
109,602
118,149
112,944
112,097
100,120
113,831
203,782
203,782113,831100,120112,097112,944118,149109,602118,447120,719184,949237,512304,163302,687272,010330,084331,076365,017371,437391,000449,102340,756309,533299,008316,396347,233468,275397,526407,417436,981358,356333,938332,389255,053296,321165,147192,522219,530141,017158,804154,962102,695110,480119,840126,051133,73933,43138,46501,6412,244
       Cash And Cash Equivalents 
1,641
-1,641
0
24,603
21,215
126,319
95,394
49,668
32,780
27,887
76,248
66,712
49,778
43,439
46,177
65,830
187,335
87,250
125,390
89,599
70,156
158,171
163,526
162,430
104,644
62,741
87,212
122,886
147,449
115,374
245,406
169,286
228,698
252,765
246,992
207,204
149,800
174,562
143,893
144,761
90,466
56,953
53,572
46,529
42,925
41,961
39,499
34,019
51,870
113,374
113,37451,87034,01939,49941,96142,92546,52953,57256,95390,466144,761143,893174,562149,800207,204246,992252,765228,698169,286245,406115,374147,449122,88687,21262,741104,644162,430163,526158,17170,15689,599125,39087,250187,33565,83046,17743,43949,77866,71276,24827,88732,78049,66895,394126,31921,21524,6030-1,6411,641
       Short-term Investments 
0
3,282
0
13,114
11,341
5,832
28,852
68,670
76,138
72,446
76,541
90,754
88,676
173,586
142,472
95,492
73,008
164,555
195,825
240,106
247,636
234,858
238,597
227,714
216,996
105,297
49,553
22,727
245
245
49,943
99,969
39,992
19,999
0
0
0
0
0
0
0
0
0
0
0
0
83,922
0
0
0
00083,92200000000000019,99939,99299,96949,94324524522,72749,553105,297216,996227,714238,597234,858247,636240,106195,825164,55573,00895,492142,472173,58688,67690,75476,54172,44676,13868,67028,8525,83211,34113,11403,2820
       Net Receivables 
0
0
0
0
135
119
114
57
48
74
48
14
33,823
0
33,823
33,823
33,823
33,823
0
281
34,216
35,852
132
688
16,666
48,435
28,888
29,654
38,864
104,872
39,115
24,466
26,853
35,233
35,005
49,690
50,875
64,582
81,869
23,094
41,065
17,781
19,572
22,592
39,290
26,620
29,765
32,170
34,368
61,538
61,53834,36832,17029,76526,62039,29022,59219,57217,78141,06523,09481,86964,58250,87549,69035,00535,23326,85324,46639,115104,87238,86429,65428,88848,43516,66668813235,85234,216281033,82333,82333,82333,823033,82314487448571141191350000
       Other Current Assets 
603
0
0
748
740
1,468
1,691
1,445
1,562
2,288
2,125
1,324
2,563
2,505
3,873
3,825
2,155
6,496
22,348
7,904
12,696
8,100
1,111
13,388
31,448
30,845
28,606
7,754
6,626
8,656
10,035
9,037
14,877
12,214
11,181
39,502
33,140
24,121
42,129
29,618
32,864
25,381
24,398
22,039
20,243
18,831
18,961
13,438
11,350
9,138
9,13811,35013,43818,96118,83120,24322,03924,39825,38132,86429,61842,12924,12133,14039,50211,18112,21414,8779,03710,0358,6566,6267,75428,60630,84531,44813,3881,1118,10012,6967,90422,3486,4962,1553,8253,8732,5052,5631,3242,1252,2881,5621,4451,6911,46874074800603
   > Long-term Assets 
0
-1,641
0
6
1,234
290
306
330
515
764
703
784
1,923
1,910
3,113
3,971
3,895
4,203
4,433
4,651
5,891
5,732
6,364
6,300
528,265
543,560
507,132
496,212
461,668
446,963
296,072
285,143
272,702
263,686
280,787
272,183
253,540
232,669
217,641
198,382
166,881
156,139
135,265
125,396
123,554
112,533
108,099
107,022
106,839
106,403
106,403106,839107,022108,099112,533123,554125,396135,265156,139166,881198,382217,641232,669253,540272,183280,787263,686272,702285,143296,072446,963461,668496,212507,132543,560528,2656,3006,3645,7325,8914,6514,4334,2033,8953,9713,1131,9101,9237847037645153303062901,23460-1,6410
       Property Plant Equipment 
0
0
0
6
30
164
181
205
210
404
398
479
540
629
1,832
2,688
2,612
2,904
2,934
3,364
3,617
3,714
3,726
3,808
8,023
41,911
42,127
42,940
39,418
37,881
36,264
34,542
35,498
33,838
32,112
30,388
40,606
39,082
37,529
35,959
34,372
32,774
18,810
17,437
16,045
14,664
13,255
11,833
10,418
9,018
9,01810,41811,83313,25514,66416,04517,43718,81032,77434,37235,95937,52939,08240,60630,38832,11233,83835,49834,54236,26437,88139,41842,94042,12741,9118,0233,8083,7263,7143,6173,3642,9342,9042,6122,6881,832629540479398404210205181164306000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
59,044
59,044
59,044
59,044
59,044
59,044
59,044
59,044
59,04459,04459,04459,04459,04459,04459,04459,04455,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,053000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
328,153
318,513
309,413
300,312
291,212
282,112
157,484
151,378
144,170
135,159
126,148
117,138
108,127
99,116
90,106
81,095
72,084
63,074
54,063
45,053
36,042
27,032
18,021
9,011
0
0
009,01118,02127,03236,04245,05354,06363,07472,08481,09590,10699,116108,127117,138126,148135,159144,170151,378157,484282,112291,212300,312309,413318,513328,153000000000000000000000000
       Other Assets 
0
0
0
0
1,204
125
125
0
0
360
305
305
1,383
1,281
1,281
1,283
1,283
1,299
1,499
1,287
2,274
2,018
2,638
2,492
137,036
128,083
100,539
97,907
75,985
71,917
47,271
44,170
64,857
39,636
67,474
69,604
640,266
39,418
34,953
26,275
94,483
5,238
3,348
0
0
0
0
0
0
0
00000003,3485,23894,48326,27534,95339,418640,26669,60467,47439,63664,85744,17047,27171,91775,98597,907100,539128,083137,0362,4922,6382,0182,2741,2871,4991,2991,2831,2831,2811,2811,383305305360001251251,2040000
> Total Liabilities 
769
0
0
2,898
3,910
6,161
4,806
6,556
6,917
8,850
5,913
14,176
11,942
53,678
62,347
68,408
232,096
228,639
279,824
238,714
244,916
245,616
247,857
261,285
360,612
324,414
304,172
327,658
376,444
391,355
374,914
358,181
396,521
414,812
437,232
465,117
449,094
509,240
459,504
422,041
342,488
291,210
280,519
274,420
272,287
252,735
253,950
257,544
269,855
285,604
285,604269,855257,544253,950252,735272,287274,420280,519291,210342,488422,041459,504509,240449,094465,117437,232414,812396,521358,181374,914391,355376,444327,658304,172324,414360,612261,285247,857245,616244,916238,714279,824228,639232,09668,40862,34753,67811,94214,1765,9138,8506,9176,5564,8066,1613,9102,89800769
   > Total Current Liabilities 
769
0
0
2,898
3,902
6,123
4,770
6,522
6,885
8,841
5,903
14,166
11,868
13,409
20,932
26,139
114,268
133,463
181,591
151,357
144,349
151,419
164,420
177,399
265,693
202,613
185,618
223,148
208,118
214,152
195,774
181,458
187,146
172,679
165,595
189,205
256,493
253,914
233,680
187,965
124,756
82,944
92,184
79,702
99,870
66,487
107,300
65,709
80,914
91,227
91,22780,91465,709107,30066,48799,87079,70292,18482,944124,756187,965233,680253,914256,493189,205165,595172,679187,146181,458195,774214,152208,118223,148185,618202,613265,693177,399164,420151,419144,349151,357181,591133,463114,26826,13920,93213,40911,86814,1665,9038,8416,8856,5224,7706,1233,9022,89800769
       Short-term Debt 
0
0
0
0
4
4
4
0
0
0
0
0
0
40,000
40,000
40,000
0
5
9
7
987
987
0
0
15,000
4,677
4,780
4,884
4,989
5,096
5,206
5,317
5,286
5,429
5,575
5,723
102,345
102,611
102,580
70,207
36,744
29,160
28,757
12,861
24,039
7,065
7,192
5,289
5,400
5,514
5,5145,4005,2897,1927,06524,03912,86128,75729,16036,74470,207102,580102,611102,3455,7235,5755,4295,2865,3175,2065,0964,9894,8844,7804,67715,00000987987795040,00040,00040,0000000004440000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
9
7
0
0
0
0
0
4,677
0
0
0
0
0
0
0
0
0
0
97,543
97,848
98,158
65,947
32,000
24,000
24,000
8,000
17,500
0
0
0
0
0
0000017,5008,00024,00024,00032,00065,94798,15897,84897,54300000000004,6770000079500000000000000000
       Accounts payable 
418
0
0
1,970
714
2,077
1,488
3,032
2,021
4,329
2,412
5,273
2,313
2,415
5,143
8,524
2,039
15,083
10,212
8,705
6,998
17,880
4,795
12,684
42,796
15,226
19,321
64,362
39,217
54,379
29,413
40,403
41,308
30,537
41,984
28,809
33,588
19,466
24,944
19,708
18,021
12,577
11,776
9,038
14,635
11,882
10,107
13,494
15,180
12,658
12,65815,18013,49410,10711,88214,6359,03811,77612,57718,02119,70824,94419,46633,58828,80941,98430,53741,30840,40329,41354,37939,21764,36219,32115,22642,79612,6844,79517,8806,9988,70510,21215,0832,0398,5245,1432,4152,3135,2732,4124,3292,0213,0321,4882,0777141,97000418
       Other Current Liabilities 
351
0
0
928
3,184
4,042
3,278
3,490
4,864
4,512
3,491
8,893
9,555
10,994
15,789
17,615
30,261
34,272
29,033
21,621
51,454
53,960
81,012
94,616
150,917
133,126
121,201
121,760
124,082
119,791
137,626
117,704
125,338
118,460
106,167
138,981
99,654
121,397
101,109
96,785
71,033
18,839
28,348
33,969
61,196
46,845
90,001
46,926
75,144
71,814
71,81475,14446,92690,00146,84561,19633,96928,34818,83971,03396,785101,109121,39799,654138,981106,167118,460125,338117,704137,626119,791124,082121,760121,201133,126150,91794,61681,01253,96051,45421,62129,03334,27230,26117,61515,78910,9949,5558,8933,4914,5124,8643,4903,2784,0423,18492800351
   > Long-term Liabilities 
0
0
0
0
8
38
36
34
32
9
10
10
74
40,269
41,415
42,269
117,828
95,176
98,233
87,357
100,567
94,197
83,437
83,886
94,919
121,801
118,554
104,510
168,326
177,203
179,140
176,723
209,375
242,133
271,637
275,912
192,601
255,326
225,824
234,076
217,732
208,266
188,335
194,718
172,417
186,248
146,650
191,835
188,941
194,377
194,377188,941191,835146,650186,248172,417194,718188,335208,266217,732234,076225,824255,326192,601275,912271,637242,133209,375176,723179,140177,203168,326104,510118,554121,80194,91983,88683,43794,197100,56787,35798,23395,176117,82842,26941,41540,26974101093234363880000
       Long term Debt Total 
0
0
0
0
0
7
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77,455
77,812
78,228
78,598
98,798
96,607
96,917
97,230
1,820
0
0
0
0
27,056
19,246
0
0
0
0
0
0
0
000000019,24627,05600001,82097,23096,91796,60798,79878,59878,22877,81277,4550000000000000000000006700000
       Other Liabilities 
0
0
0
0
0
31
30
34
28
9
10
10
68
40,269
41,415
42,269
117,823
95,176
98,233
87,357
100,567
94,197
83,437
83,886
94,919
90,497
88,485
75,699
64,993
74,924
77,940
76,621
88,376
122,341
152,985
158,425
158,898
222,745
194,091
203,393
158,249
154,552
158,369
0
0
0
0
0
0
0
0000000158,369154,552158,249203,393194,091222,745158,898158,425152,985122,34188,37676,62177,94074,92464,99375,69988,48590,49794,91983,88683,43794,197100,56787,35798,23395,176117,82342,26941,41540,26968101092834303100000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
102
40,257
41,406
42,262
117,801
95,150
98,209
87,334
100,545
94,176
83,368
2,421
9,637
3,874
3,029
1,752
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,7523,0293,8749,6372,42183,36894,176100,54587,33498,20995,150117,80142,26241,40640,257102000000000000
> Total Stockholder Equity
1,475
1,475
0
35,572
30,755
127,867
121,552
113,614
104,078
94,609
149,752
145,412
130,998
167,762
133,288
100,710
68,120
30,617
56,998
99,875
119,331
197,097
165,924
142,541
635,928
566,379
519,356
467,562
394,757
396,364
370,260
317,962
247,618
213,891
174,631
137,150
76,456
26,116
62,300
13,853
9,342
-14,352
-26,807
-39,422
-30,584
-27,258
-33,754
-50,402
-49,185
24,581
24,581-49,185-50,402-33,754-27,258-30,584-39,422-26,807-14,3529,34213,85362,30026,11676,456137,150174,631213,891247,618317,962370,260396,364394,757467,562519,356566,379635,928142,541165,924197,097119,33199,87556,99830,61768,120100,710133,288167,762130,998145,412149,75294,609104,078113,614121,552127,86730,75535,57201,4751,475
   Common Stock
0
0
0
0
0
0
0
-120,170
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
1
2
2
2
2
2
2
2
2
2
2
2
2
2
222222222222212221111111111110000000000000-120,1700000000
   Retained Earnings Total Equity0000000-1,595,075-1,579,130-1,552,913000-1,460,351-1,389,673-1,330,129-1,247,091-1,177,511-1,090,511-1,030,552-854,801-794,054-699,571-644,986-586,816-514,395-454,341-428,294-394,225-374,050-386,330-363,196-341,679-297,136-259,274-222,966-187,187-161,389-141,532-122,057-111,368-100,673-90,303-80,955-73,33600000
   Accumulated Other Comprehensive Income 
0
-59,588
0
0
-1
-9
-8
-52
-56
-8
-27
-7
-234
-27
37
-7
-42
-179
-254
-181
-442
-550
-459
-409
-261
-36
23
6
0
-4,189
-9
6
13
9
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
66666666666666669136-9-4,1890623-36-261-409-459-550-442-181-254-179-42-737-27-234-7-27-8-56-52-8-9-100-59,5880
   Capital Surplus 
0
0
0
0
0
201,203
202,536
204,048
204,969
206,146
271,998
287,113
292,783
355,138
356,217
359,991
365,298
372,475
420,448
486,386
493,823
591,871
594,676
597,290
1,150,583
1,153,230
1,164,318
1,167,126
1,188,810
1,251,164
1,400,820
1,408,466
1,425,115
1,460,971
1,504,752
1,526,815
1,536,800
0
0
0
1,562,247
1,564,770
1,568,260
0
0
0
0
0
0
0
00000001,568,2601,564,7701,562,2470001,536,8001,526,8151,504,7521,460,9711,425,1151,408,4661,400,8201,251,1641,188,8101,167,1261,164,3181,153,2301,150,583597,290594,676591,871493,823486,386420,448372,475365,298359,991356,217355,138292,783287,113271,998206,146204,969204,048202,536201,20300000
   Treasury Stock000000000000000000000000000000000000-162-162-162-162-161-162-79-21000000
   Other Stockholders Equity 
0
0
0
0
-63,365
-133,827,206
-252,512,651
203,969
204,807
205,985
271,836
286,951
292,621
354,976
356,217
359,991
365,298
372,475
420,448
486,386
493,823
591,871
594,676
597,290
1,150,583
1,153,230
1,164,318
1,167,126
1,188,810
1,251,164
1,400,820
1,408,466
1,425,115
1,460,971
1,504,752
1,526,815
1,536,800
1,548,880
1,555,788
1,559,206
1,562,247
1,564,770
1,568,260
1,570,134
1,578,358
1,599,669
1,601,755
1,605,146
1,629,167
1,696,821
1,696,8211,629,1671,605,1461,601,7551,599,6691,578,3581,570,1341,568,2601,564,7701,562,2471,559,2061,555,7881,548,8801,536,8001,526,8151,504,7521,460,9711,425,1151,408,4661,400,8201,251,1641,188,8101,167,1261,164,3181,153,2301,150,583597,290594,676591,871493,823486,386420,448372,475365,298359,991356,217354,976292,621286,951271,836205,985204,807203,969-252,512,651-133,827,206-63,3650000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue160,180
Cost of Revenue-63,177
Gross Profit97,00397,003
 
Operating Income (+$)
Gross Profit97,003
Operating Expense-147,475
Operating Income-50,472-50,472
 
Operating Expense (+$)
Research Development37,652
Selling General Administrative106,545
Selling And Marketing Expenses0
Operating Expense147,475144,197
 
Net Interest Income (+$)
Interest Income0
Interest Expense-18,185
Other Finance Cost-0
Net Interest Income-18,185
 
Pretax Income (+$)
Operating Income-50,472
Net Interest Income-18,185
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-69,410-31,534
EBIT - interestExpense = -68,657
-69,410
-51,225
Interest Expense18,185
Earnings Before Interest and Taxes (EBIT)-50,472-51,225
Earnings Before Interest and Taxes (EBITDA)-13,721
 
After tax Income (+$)
Income Before Tax-69,410
Tax Provision-0
Net Income From Continuing Ops-69,410-69,410
Net Income-69,410
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses171,332
Total Other Income/Expenses Net-18,93818,185
 

Technical Analysis of Akebia
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Akebia. The general trend of Akebia is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Akebia's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Akebia Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Akebia Ther.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.87 < 4.0758.

The bearish price targets are: 3.46 > 2.48 > 2.48.

Know someone who trades $AKBA? Share this with them.👇

Akebia Ther Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Akebia Ther. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Akebia Ther Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Akebia Ther. The current macd is 0.15355501.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Akebia price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Akebia. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Akebia price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Akebia Ther Daily Moving Average Convergence/Divergence (MACD) ChartAkebia Ther Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Akebia Ther. The current adx is 38.42.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Akebia shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Akebia Ther Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Akebia Ther. The current sar is 3.95309037.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Akebia Ther Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Akebia Ther. The current rsi is 58.46. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Akebia Ther Daily Relative Strength Index (RSI) ChartAkebia Ther Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Akebia Ther. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Akebia price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Akebia Ther Daily Stochastic Oscillator ChartAkebia Ther Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Akebia Ther. The current cci is -53.67317776.

Akebia Ther Daily Commodity Channel Index (CCI) ChartAkebia Ther Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Akebia Ther. The current cmo is 7.85707137.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Akebia Ther Daily Chande Momentum Oscillator (CMO) ChartAkebia Ther Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Akebia Ther. The current willr is -60.97560976.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Akebia is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Akebia Ther Daily Williams %R ChartAkebia Ther Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Akebia Ther.

Akebia Ther Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Akebia Ther. The current atr is 0.18990296.

Akebia Ther Daily Average True Range (ATR) ChartAkebia Ther Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Akebia Ther. The current obv is 26,284,049.

Akebia Ther Daily On-Balance Volume (OBV) ChartAkebia Ther Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Akebia Ther. The current mfi is 46.14.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Akebia Ther Daily Money Flow Index (MFI) ChartAkebia Ther Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Akebia Ther.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Akebia Ther Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Akebia Ther based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.457
Ma 20Greater thanMa 503.668
Ma 50Greater thanMa 1003.069
Ma 100Greater thanMa 2002.512
OpenGreater thanClose3.630
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Akebia with someone you think should read this too:
  • Are you bullish or bearish on Akebia? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Akebia? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Akebia Ther

I send you an email if I find something interesting about Akebia Ther.


Comments

How you think about this?

Leave a comment

Stay informed about Akebia Ther.

Receive notifications about Akebia Ther in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.